Combomed Pharma launches Crystaderm™ for acne treatment

Combomed Pharma has launched Crystaderm™, a new over-the-counter product aimed at treating skin conditions like acne and impetigo. This innovative treatment contains 1% hydrogen peroxide, which is released gradually to combat various microorganisms. Crystaderm™ is notable for being gentle on the skin and not contributing to antibiotic resistance, a significant issue in healthcare today. The product is manufactured in Montreal, Canada. This local production helps to reduce transportation impacts on the environment and ensures a steady supply. It also adheres to strict Canadian quality standards. Crystaderm™ is effective for mild to moderate acne and has shown comparable results to benzoyl peroxide but with less irritation. With rising concerns about substance contamination in some acne treatments, Crystaderm™ offers a safer alternative without harmful risks. In addition to acne, Crystaderm™ can also treat localized non-bullous impetigo, a skin infection that mainly affects children. The product is suitable for individuals aged two and older and avoids the common risks of bacterial resistance. Crystaderm™ is now available in pharmacies throughout Canada. Combomed Pharma, founded by three pharmacists in 2019, aims to create healthcare solutions that prioritize both patient safety and environmental responsibility.